Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
-
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions,...
-
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions,...
-
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”) a medical technology company delivering intelligent, rapid, non-invasive testing solutions,...
-
Gross profit increase of 32.6% and 11-point gross profit margin increase driven by higher-margin cartridge sales Submitted FDA 510(k) and remain on track for planned expansion into multi-billion...
-
NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
-
Avon Freight Group selects INBS’ fingerprint drug testing for three UK sites, reinforcing workplace safety and efficiency INBS surpasses 400+ accounts in 19 countries, targeting aggressive U.S....
-
Gross profit expected to surge by 32.6% Unaudited revenue of $0.61 million for fiscal Q2 and $1.48 million for the six months ended December 31, 2024 Higher-margin cartridge sales driving...
-
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
-
Quantum Traffic Management transitions from saliva and urine testing to non-invasive, in-house fingerprint sweat-based drug screening Most recent client added to INBS’s portfolio of more than 400...